Naproplat Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Carboplatin

Indications/Uses

Advanced ovarian cancer, small cell lung cancer, head, neck & genitourinary cancer, particularly in testicular, bladder & cervical cancers. Ped brain tumor (medulloblastoma).

Click to view Naproplat detailed prescribing information

Dosage/Direction for Use

IV 400 mg/m² infusion over 15 min to 1 hr. Not to be given more frequently than every 4 wk & should be reduced in patient at risk of myelosuppression. Lower doses may be given as part of combination regimens.

Click to view Naproplat detailed prescribing information

Overdosage

View Naproplat overdosage for action to be taken in the event of an overdose.

Contraindications

History of severe allergic reaction to cisplatin or other platinum-containing compd. Severe bone marrow depression or significant bleeding.

Click to view Naproplat detailed prescribing information

Special Precautions

Anaphylactic-like reactions. Possible bone marrow suppression; anemia. Can induce emesis; may be reduced by premed w/ antiemetics. Concomitant treatment w/ aminoglycosides. Vision loss may occur w/ high doses. Needles or IV administration sets containing Al parts may cause precipitate formation & potency loss. Carboplatin is mutagenic in vivo & in vitro. Advise women of childbearing potential to avoid becoming pregnant. Pregnancy. Recommend to discontinue breastfeeding during treatment. Increased incidence of peripheral neurotoxicity in patients >65 yr & in those previously treated w/ cisplatin.

Click to view Naproplat detailed prescribing information

Use In Pregnancy & Lactation

Click to view Naproplat detailed prescribing information

Adverse Reactions

Bone marrow suppression, thrombocytopenia, neutropenia, leucopenia, anemia; vomiting, nausea, other GI effects (eg, diarrhea, constipation); peripheral neuropathies, mild paresthesias; abnormal LFTs; decreased serum electrolyte values; hypersensitivity; pain & asthenia.

Click to view Naproplat detailed prescribing information

Drug Interactions

Increased renal &/or audiologic toxicity w/ aminoglycosides.

Storage

View Naproplat storage conditions for details to ensure optimal shelf-life.

Description

View Naproplat description for details of the chemical structure and excipients (inactive components).

Action

View Naproplat mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

Regulatory Classification

Presentation/Packing

Form

Naproplat soln for IV infusion 10 mg/mL

Packing/Price

15 mL x 1's;45 mL x 1's

Naproplat

carboplatin

Manufacturer:

Naprod

Distributor:

Multicare

Marketer:

Multicare